News

Panion will not renew Letter of Intent with GeneQuine

The board of directors for Panion Animal Health AB decided at their meeting of 4 December 2017 to
focus Panion's efforts on the development of the epilepsy project. This means that we will no longer pursue the dialogue and cooperation with GeneQuine Biotherapeutics GmbH with regards to their veterinary gene therapy projects. The mutually agreed Letter of Intent will therefore not be sought renewed or extended upon expiry on the 31 December 2017. The decision was taken for business reasons with the aim to focus on the opportunities that best fit with Panion's strategic plans and have the potential to create the best future value for Panion's shareholders.

"Panion will continue to evaluate human medicines projects that may carry great potential for development in veterinary medicine" says Anja Holm, CEO of Panion. 

DECEMBER 5 2017

For further information, please contact:

Anja E. H. Holm, CEO | + 45-22 94 66 00
anja.holm@panion-animalhealth.com 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 

2018-02-22

Period October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -854 (-643).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -4 200 (-692).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)
2018-01-19

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.

2018-01-09

Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.

2018-01-03

Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.

2017-12-29

Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.

1
2
...
7
>>

Subscribe

Press releases and reports via E-mail.